Altair
Skip to content

Trading Analysis Report: ANET

Analysis date: 2026-10-14 · Model: claude-opus-5-5 · AI-generated, not financial advice.

  • Analysis date: 2026-10-14
  • Rating: Hold
  • Generated: 2026-10-14 16:36:54
  • TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
  • Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
  • Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

V. Portfolio Manager Decision

Rating: Hold

Executive Summary: Hold ANET at $195.42. Make no new purchases, no starter and no resting order at $183 before the Oct 29 FOMC and the Q3 print (date unconfirmed, likely early November), and keep core positions at or below standard weight. Run a 17% loss test (FOMC -5% then a -12% print gap compounds to about -16.4%, near the 200 SMA at $162.16). Accounts that fail it, or have no stated loss budget, should either hedge through the print within a pre-set cost cap or trim at least ~13% in two halves, the first by the close before the first event in the cluster and the second by the last close before the print (the Oct 30 close if the date is still unconfirmed). Two closes below $181 cut the position to about ⅔ of standard weight; upgrade to Overweight only through close-confirmed staging after a clean Q3 and guide, on a 1-3 month horizon with a $200 target.

Current Price: 195.42

Price Target: 200.0

Confidence: Medium

Time Horizon: 1-3 months

IV. Risk Management Team Decision

Aggressive Analyst

Aggressive Analyst: Nobody else has spoken yet, so I'll set the frame and then get ahead of what I expect to hear.

First, Hold is not the timid choice here. It's a loaded position. We keep the thesis, we keep our powder dry, and we've pre-committed to buying aggressively at 183 or on a clean print. The aggressive move isn't to spend ammunition at 195 with no edge. It's to spend it where the skew is best, and 183 is that spot. It's about 35x forward EPS, it sits roughly two ATRs below the current price, and it lines up with the September lows around 181 to 189. From 183, getting back to the 10 EMA and Bollinger midline near 206 is about 13%, and getting back to the highs is nearly 19%. Even a full trip to the 200-day at 162 is only about 11% below 183.

Now what I expect from the conservative side: sell, or at least trim hard. The case would be that the price is below the 50-day, MACD has crossed bearish, the stock trades at 61.6x trailing earnings and 23x sales, gross margin is down 230 to 340 basis points, and insiders have sold about $1.4 billion with no buying.

My answer is that the higher-timeframe picture doesn't support selling. Weekly and monthly SuperTrend are both up, price is nearly 25% above the weekly stop and 20% above the 200-day, and the daily z-score is minus 1.97. Selling now means paying the market's fee after a 9.8% three-day cascade, and none of our news shows a guidance cut, a downgrade, or anything company-specific. BNP just raised its target to $290. The macro tape explains the drop: hot CPI, the 10-year up, Nasdaq down 1.65%, and money rotating out of chips. That's multiple compression, not thesis damage.

The margin worry is also overstated. Gross margin has been flat at 62 to 63% for three quarters, and it actually rose from 61.9% to 62.9% last quarter. Opex grew about 17% against 38% revenue growth, so operating income grew 39.8%, faster than revenue, even with the gross margin dip. On insiders, $1.4 billion is about half a percent of a $246 billion market cap. The CEO has sold continuously for over a year while the stock went from about $102 to $217, and the cadence looks systematic. I wouldn't ignore it, but it's not a reason to exit a business growing this fast.

The cash flow dip doesn't change that either. Q2 operating cash flow was down 10% year over year, but Q1 ran at 166% of net income, and H1 operating cash flow is about 124% of net income and up 51% year over year.

I'll concede the valuation point. The $5.22 forward EPS is a steep ramp from a $3.80 annualized run-rate. That's why the plan's upgrade trigger requires guidance that supports it, not just a good quarter.

Now the neutral side, which I expect to propose a starter position at 195 because the higher-timeframe trend is up and we shouldn't be all-or-nothing. That's the weakest option, because it spends risk with no edge. ADX is 20, so there's no trend to ride. The daily SuperTrend stop is 0.42% away and can flip on noise. RSI and the MACD histogram are making 30-day lows, and the daily TD count is only at 3 of 9, so this isn't exhausted yet. ATR is expanding. The stock has also gapped about 10% on what look like earnings reactions, down in May and up in August before fading to close at 197.31. A starter here buys a worse average price than 183 to 188, burns risk budget before the FOMC on October 29 (hike odds up 15 points in a week to 30%) and the likely early-November print, and leaves less room to size up where the payoff is better. The cost is real but small: if the stock bounces to 207 without touching 188, we miss maybe 6%. Against a 10 to 15% gap in either direction, I'll take that trade. And we aren't locked out, because a print with revenue of at least $3.2 billion, gross margin near 62%, and guidance supporting $5.2 triggers the upgrade anyway. Paying up for a de-risked grower beats owning the coin flip.

Also, the 181 level isn't a literal two-point stop, which would be inside noise at an ATR of 7.67. It's a close-below trigger that cuts to two-thirds of standard weight, which is sensible.

I do have two pushbacks on the plan. The one-third cap at 183 is timid if the thesis holds, so I'd want room to scale beyond it on a hold of 181 to 188 with a fresh fundamental check. And the trim-into-strength rule should apply only to excess weight, not to positions at standard size. Neither changes the call.

One caution is that retail posts say the stock traded under $190 today, while our tape shows a low of 193.30 and a close of 195.42. The bar may still be forming, so check the live price, because if we're already near 188 the setup is closer than the plan assumes.

I back Hold: no selling, no starter, and a loaded order at 183. Aggressive Analyst: Let me start with what I'll give up, because you've both earned some of it. 183 is about 1.6 ATRs below the close, not two. The conservative is right that 48x the run-rate is the honest multiple if the $5.22 doesn't show up. The 200-day isn't a floor, and I shouldn't have leaned on it. The neutral is also right that I was arguing against an order that isn't live yet, because the plan gates any add behind the 10-Q review and the October 29 FOMC.

I'll take the neutral's fix on the 181 trigger too. Two closes, not one. A single close two points under a fresh fill is noise, and getting shaken out on noise means paying the spread twice. I'll also drop my push to scale past a third before the print. If earnings land in early November as usual, that's about a week after the FOMC, and that week isn't worth fighting for. The date is unconfirmed, though.

Here's where I hold the line. Neutral, you said my objection to the starter applies to my own order. It doesn't, because the objection was never "don't take event risk." It was "don't take it at a price that doesn't pay you." The event risk is identical at 195 and 183. Whatever the stock is worth the morning after the print, it doesn't know what we paid, so a 183 entry beats a 195 entry by about twelve dollars in every scenario where we fill. The only cost is the scenario where we don't fill, and there we took no risk. That's why the 6% isn't second-order. It's the whole difference between a position with an edge and one without.

Conservative, you say a resting order fills when something bad is happening. Of course it does. That's what buying support means. But this order has filters. If the 10-Q shows the 68% jump in current liabilities is payables and purchase commitments rather than deferred revenue, there's no fill. If it fills after a hawkish FOMC, we're paying 35x forward for 38% growth at a 45% operating margin, after a repricing that's already partly in the stock. It's sized at a third of standard, so a 15% gap against that tranche costs about 5% of one standard allocation. The downside is bounded by size, not by a stop. I agree stops don't fill through gaps.

On the macro, you cite 30% hike odds, but 68% for a hold is the modal outcome. After a 15-point weekly swing toward a hike, a hold is a relief relative to the path. Recession is priced at 8% and an AI bubble burst in 2026 at 6%. That is real money saying multiple stress, not thesis damage. I'll concede the beta math, though. 1.6 times 1.65% is about 2.6%, and ANET fell about 4.5% Wednesday, so roughly two points aren't explained by an undated Nasdaq headline. I'd call that chip rotation and positioning after an 87% run from the March close. It still isn't a company-specific negative, which is the only claim I made.

On "you can't have it both ways," I'm not. I never used the minus 1.97 z-score to justify buying at 195. I used it against selling here. Stretch is a reason not to pay the fee after the cascade, not a reason to buy. My reason to buy at 183 is price structure. The last time the stock tested 188 was September 14, and it was back at 205 within a week and 217 within four weeks. That's one example, not a pattern, and I know it.

The "20% above the 200-day measures how far it can fall" argument proves too much. It would have kept you out of the move from 116 to 217, which was driven by 36% earnings growth. The weekly stop doesn't protect against a 15% drawdown, agreed, but it tells you which direction pullbacks tend to resolve in a name like this. As for the monthly TD 7, it can't complete before the end of November, so it says nothing about the 29th.

On cash flow, the neutral already made the point. Q2 last year converted at 135% of net income, so 89% is a dip from an elevated base, not a clean read. H1 operating cash flow is up 51%, and trailing free cash flow is about 96% of net income. The current liabilities question is real and open, which is why the 10-Q review is a gate and not an afterthought. The gross margin dip is real too, but operating income still grew 39.8% against revenue growth of 37.7%. If gross margin slips below 62%, the upgrade trigger catches it.

You're right on insiders. Half a percent of market cap was the wrong yardstick, and 460,000 shares was 6.6% of that day's volume. Part of the dollar doubling in CEO sales is just the stock being far higher than it was in April through July, though I can't split share counts by period from what we have. The bigger point is where the supply sits: the CEO sold at 211 to 217 and Bechtolsheim at 199. That supply is above us. A buyer at 183 is below it, and a chaser at 199 to 207 is not. That's why I'd trim excess into strength and buy low.

Conservative, I can't back trimming everyone to two-thirds. A $3.2B revenue print is only about 5% sequential growth after roughly 9% and 12% in the last two quarters. The hard leg is guidance. If the print is clean, you've sold a third of the position and have to buy it back higher or live smaller in the one scenario you wanted to own. The neutral is right that if standard weight can't survive a gap, fix the weight, and measure excess against target weight, not cost. I'm skeptical of the options route as a default. Protection bought into the print is bought at peak demand, and our data has no implied vol, so that's something to check. A zero-cost collar also sells the upside in the clean-print case, which is the case that pays. It's fine for holders who are uneasy, but I wouldn't force it.

On the live-price question, we agree on closes. If the stock really traded under 190, the sensible move is to finish the 10-Q work now so the FOMC is the only gate left.

Here's where I want the aggression. It's not an extra third at 183. It's the print. Pre-commit now: if revenue is at least $3.2B, gross margin holds near 62%, and guidance supports about $5.2, go to full weight even if the stock gaps to 215. That's when the coin flip is gone, and paying up for a de-risked grower beats owning the coin flip. Until then, the plan stands: no sell, no starter, no blanket trim, a gated add at 183, and size for the gap. Waiting costs about 6%, and paying 195 now costs twelve dollars for no new information. I back the Hold. Aggressive Analyst: Most of the argument has settled, so I'll start with what I'm giving up.

The resting order at 183 is gone. The neutral's point about trigger distance did it. A fill at 183 sits a quarter of an ATR above the 181 line, while a fill around 187 sits about three quarters of an ATR above it. The conservative's 176 example, where the plan says to buy and cut in the same breath, is a real flaw in a limit order. So I'll take the close-based version for underweight accounts. After the 10-Q review and the FOMC, two closes inside 181 to 189 earns a third of standard weight, and two closes below 181 means no add. That uses the same two-close standard in both directions. I'll also admit that from 187 the skew to the 10 EMA versus the 200-day is roughly even. That makes the tranche worth about 2% of a standard allocation either way, and I'm done fighting over it.

I'm not giving up the core. Conservative, your own arithmetic doesn't get you to two-thirds. The neutral is right that 15% more ATR justifies about 13% less size, not 33%. The other 20 points come from the gap argument, and that is a loss-budget question none of us can see. The plan already says to size for a 10 to 15% gap. "Standard was set before ATR expanded" is a guess. ANET gapped about 10% down in May and about 10% up in August, so gap risk was a known feature of this name. I'll back the neutral's test. If the account can absorb 15% on the full position, it holds standard weight. If it can't, it's overweight and the fix is the weight.

I'll also take the neutral's structure for true excess, measured against target and not cost. Trim half before the 29th and half into a bounce toward 199 to 207. That is the plan's own rule with a date on it, and the excess is smaller than it was a week ago. The stock is about 9.8% below the 216.74 close, so anything that was at target on October 9 has already drifted down in weight by about that much. What I won't accept is a default one-third haircut on at-target positions. The neutral calls it a variance decision with no edge, but I do have a mild directional view: weekly and monthly trends are up and revenue growth is accelerating. A trim gives up that positive drift, and that's worth paying only if variance exceeds the account's budget, which is exactly what the test checks.

On hedging, the neutral is right that a collar answers my peak-demand objection much better than a bare put, because selling call vol offsets the cost of buying puts. My remaining objection is small. A cap near 220 is only 12.6% above here and bites only in the clean-print case. If the account fails the loss test and the quote is sensible, a collar beats selling a third at the low of a 9.8% three-day drop, because it keeps the shares through the print. If the account passes, it needs no hedge. We have no implied vol, so get the quote before deciding.

On cash flow, the conservative handed me something useful. Current liabilities rose $1.18B in Q1 and only $258M in Q2, while conversion fell to 89%. So the Q2 shortfall wasn't liabilities-driven. If the neutral's inference holds, at least $4.8B of the $6.9B deferred revenue sits in current liabilities, about 70% of the $6.8B total. That balance is also roughly two and a quarter quarters of Q2 revenue already prepaid. That is conditional on the period matching, but it's the benign reading of the liabilities. It also points the 10-Q review at the asset side: receivables, inventory and purchase commitments. That's where a Q2 conversion dip would show up, and trailing FCF at 96% of net income suggests it isn't alarming.

On the print, I'll accept staging. August is the reason. The stock opened at 210.19 and closed at 197.31, a roughly 6% reversal inside one day on a beat. So the first half goes in at the first confirmed close after a clean print, and the second half on a second close or a retest. I'd put a limit of about five sessions on that, so staging doesn't turn into waiting forever. I'll also take the neutral's correction on the bar. $3.2B against $2.308B is 38.6% year over year, above Q2's 37.7%, so it's a hold-the-growth-rate bar and guidance is the real gate. That's why I'm comfortable paying up after the information arrives instead of before. Paying up for a de-risked grower beats owning the coin flip.

Conservative, your macro and insider points are fair, and I take both. The 30% hike tail is why nothing gets added before the 29th, and price-agnostic sellers like Bechtolsheim and Duda are supply at 183 as well as above us. But neither argument supports selling core weight after a roughly 10% drop. They support buying only with confirmation and not chasing, which is what the plan says.

So I back the Hold on these terms. There's no starter and no resting order. This week the 10-Q review, the earnings date and a collar quote get done. Only true excess is trimmed, and the core is sized by the loss test. Underweight accounts add a third at most, on a close, after the FOMC. The upgrade is staged after a clean print with supportive guidance. Waiting costs about 2% of a standard allocation. Selling a third of the core before a clean print costs more than that, and it also leaves us buying back higher. The aggressive move is to keep the core and the powder for the one event that removes the coin flip. Aggressive Analyst: Let me start with what I'm taking back, because the last round cost me a few arguments I shouldn't have made.

I leaned on trailing free cash flow at 96% of net income as comfort. The neutral's split shows why that was lazy: the halves ran roughly 105%, 66% and 120%, so 96% is an average of a weak half and a strong one, not a run-rate. I also called deferred revenue "prepaid" and talked about two and a quarter quarters of revenue already banked. For a hardware company, deferred revenue can be shipped-and-invoiced product with a receivable and no cash. The $4.8B figure is a floor built on a headline with no period, so it's a question for the 10-Q, not a finding. And a five-session cap on staging should be a decision point, not a forced buy. Forcing the second half in at any price is the chase at 211 to 217 that I told you not to make.

I'll also take the conservative's three terms on the core. Someone who can't state a loss budget takes the 13% in halves, which only restores the risk they sized for. Testing against 17%, the distance to the 200-day, instead of 15% is fine. And drift has to be counted across the whole book, because other chip names fell with this one. Folding the optional add into post-print staging if the date lands within a few sessions of the FOMC is fine too. It's worth about 2% of a standard allocation and isn't worth another round.

Now where I push back.

First, August is being read backwards. The conservative uses it to show good news gets sold. But the stock opened at 210.19 and closed at 197.31 off a prior close of 190.51, so a holder was up 3.6% on the day. A 13% trim the day before would have given up about half a percent of the position. In May the stock gapped from 170.22 to a 153 open, and by August 4 it closed at 190.51, 12% above the pre-gap close. Both gaps were followed by higher prices. August is a lesson about entry: don't chase the open, wait for closes. That is already in the staging rule. It isn't evidence for selling core weight, and it isn't evidence against it either. That's why the loss test should decide.

Second, the collar strikes. A put at 175 to 180 and a call at 215 to 220 from 195.42 is 8 to 10% down and 10 to 13% up. That is the size of the last two gaps, so the collar sells the move we're worried about and protects only what lies beyond it. It's a trim we can't undo until expiry. It also conflicts with the upgrade. If the print is clean and the stock gaps to 218, we're capped just as we want to go to full weight. If the account fails the test and the quote is sane, use it, but expire it at the first listed date past the print so the cap falls away when the information arrives. Price a put spread against it too, because that doesn't sell the clean-print upside. We have no implied vol, so the quote decides.

Third, the upgrade rule, where I do want to be bold. The conservative is right that $3.2B is about a dollar a share and doesn't validate $5.22. The neutral is right that the period is unknown. If $5.22 is calendar 2027, my "35x at 183" was a year-out multiple dressed as a near-term one, and I'll stop leaning on it. So I accept observable inputs: a Q4 revenue guide around $3.35 to $3.45B, a gross margin guide at or above 62%, and an operating margin guide in the mid-40s, with Q3 at $3.2B as the entry ticket only. First stage goes in on the first post-print close that clears those bars and holds above the pre-print close. The second goes in on a second higher close or a retest that holds the gap's midpoint, with a reassessment at five sessions rather than a forced buy.

If the bars clear and the stock still gaps down, as it did in May, that is the setup I want most. The information is good, the price is the only variable, and the two-close rule keeps us from catching a knife. Nobody here has offered a reason to pay up before that information arrives.

On the 10-Q, I'd add one thing to the neutral's point. It has been public since August, and the market paid 217 with it in hand. A fail would be news to us, not necessarily to the market. I'd still read it this week, with the pass and fail conditions written down first.

We're now arguing over roughly 2% of a standard allocation on either side, so I back the Hold on these terms:

  • Before the print: no starter, no resting order and no add.
  • This week: finish the 10-Q review, confirm the earnings date and get the collar and put spread quotes.
  • Core sizing: apply the loss test, trim at least 13% in halves if it fails, and trim true excess against target weight.
  • After the print: stage the upgrade on observable guidance.

Paying up for a de-risked grower beats owning the coin flip. Aggressive Analyst: I'll keep the concessions short, since most of them are already on the table, and then spend my time on where I think the caution is still overcorrecting.

The conservative caught a real collision in my close. I said a clean print followed by a gap down was the setup I wanted most, and I also said the first stage needs a close above the pre-print level. Those can't both be true. The neutral's single rule fixes it: nothing on print day. The first half goes in after the second close that holds above the print-day low, provided the guide cleared the bars. The second half goes in on a higher close or a retest that holds, with a review at five sessions, not a forced buy. I'll take that in both directions.

I'll also take the tighter margin bar. The May evidence is thin, because two events can't separate margins from a 47% run in five weeks. But Q2 printed 62.9% gross margin and 45.4% operating margin, so asking for a guide midpoint near 62.5 or better and refusing anything in the 61s costs us nothing if the business is what we think it is.

On the $5.22, you're right that it can't be calendar 2026. H1 EPS is 1.75, so the second half would need about 3.47. I'll stop using 35x as a near-term multiple. But the other reading matters. If it's calendar 2027, $5.22 against roughly $3.85 is about 35% growth, which is just today's 36% EPS growth carried one more year. That's no deceleration, not a hockey stick. If it's the next twelve months, it's steep. The Q4 guide helps tell us which, so the guide is the gate.

On hedging, I agree with the ranking. A put near 180 does far more against a 15% gap to about 166 than a 13% trim, which saves roughly 1.3 points of the position and gives it back on the way up. I'd choose by price, not taste. Quote the collar, the put spread and the trim against the same two numbers: what each costs if the print is clean and the stock gaps up, and what each saves on a 15% gap down. Take the cheapest protection per point saved. If the collar only works with a call near 215, take the put spread. And expire it just past the print, so the hedge falls away when the information arrives.

Now where I hold the line. Conservative, your closing line is that being full-size and unhedged into two gap events costs several times what waiting costs. That's only true for accounts that fail the loss test, and the test tells us which those are. An account that can absorb 17% on its full position, and sized this name knowing it gapped about 10% each way in May and August, isn't being careless. Nobody should pay for protection they've already sized for.

The two events also aren't the same kind. The FOMC is an intraday event in a session we can trade, with an ATR of 7.67, about 3.9% of the price. The print, if the date holds, is an overnight gap we can't trade. So for an account that fails the test, the 29th is a good first-half date because it gives ten sessions to catch a bounce, but the hard deadline for the rest is the last close before the print.

On the gap-down-on-clean-numbers case, you say the market is telling us it sees a risk we don't. That's one hypothesis. Positioning and rates are another. The two-close rule is how we find out which without guessing. If the stock can't hold the print-day low through two closes after a clean guide, we don't add, and you were right at no cost. If it holds, we bought confirmed numbers at a discount to the pre-print price. A bar nobody can clear isn't discipline. It's a decision never to buy.

On cash flow, I agree the FCF ratio is no longer a pillar for owning or selling. The neutral's answer to your filing point is the right one. The June 10-Q didn't change, and the stock still lost 10% in three sessions, so the drop isn't a verdict on it. The 10-Q stays a composition check with written pass and fail terms.

The edge here isn't predicting the print. It's being ready the moment the guide lands. That means consensus pulled, the 10-Q terms written, the bars set, sizes pre-committed and hedge quotes in hand, so stage one is a decision that takes minutes. That preparation this week is the aggressive act.

I back the Hold on the neutral's version, with two edits. The hedge-versus-trim choice is made on price, and only for accounts that fail the test. And the second half of any trim has a hard deadline at the last close before the print. Refresh the bar before acting on anything, since the 193.30 low and "under 190" can't both be right.